Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Colorectal Neoplasms 56Carcinoma, Non-Small-Cell Lung 35Breast Neoplasms 29Neoplasm Metastasis 23Glioblastoma 23Colonic Neoplasms 23Rectal Neoplasms 19Ovarian Neoplasms 16Neoplasms 15Brain Neoplasms 12Lung Neoplasms 11Pancreatic Neoplasms 10Glioma 10Fallopian Tube Neoplasms 10Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 9Gliosarcoma 7Adenocarcinoma of Lung 7Kidney Neoplasms 6Liver Neoplasms 5Astrocytoma 5Sarcoma 4Recurrence 4Oligodendroglioma 4Melanoma 4Uterine Cervical Neoplasms 3Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2

Interventions

Paclitaxel 2Doxorubicin 2talimogene laherparepvec 1sintilimab 1pazopanib 1Trabectedin 1TTI-621 1Cyproheptadine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hemangiosarcoma × Bevacizumab × Clear all
NCT01055028 2018-03-26

Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma

Stanford University

Phase 2 Terminated
18 enrolled 13 charts
Sarcoma

Hemangiosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡